About Qureight.

Our mission is to advance understanding of lung and heart disease, revolutionise clinical trials and accelerate drug development. We were founded by doctors, scientists and engineers and are based in Cambridge, UK.

Our values

01.

We first do no harm

We bring together diverse partners from across the health and life sciences ecosystem, leading with trust and integrity.

02.

We are ambitious for impact

We are an ambition-driven team, constantly breaking through the status quo to push the boundaries of what is possible in drug development and scientific research.
Improving patient outcomes is core to our ethos and moral compass.

03.

We listen

The future requires new ways of thinking, working and being. We know that our collective difference in ideas, perspectives and experiences opens up new, unmissable possibilities.

Management Team

Dr. Muhunthan Thillai

Chief Executive Officer & co-Founder

Muhunthan has over 20 years experience in thoracic medicine and is a board certified Pulmonologist. He qualified as a doctor from Imperial College London and undertook specialist medical training in Oxford where he was appointed as a member of the Royal College of Physicians. He was awarded a PhD in molecular immunology from Imperial College London before being appointed as a consultant physician. He was previously Director of Interstitial Lung Diseases at Royal Papworth and Addenbrooke’s Hospitals Cambridge UK and is currently an Honorary Associate Professor at the University of East Anglia.

Dr. Simon Walsh

Chief Scientific Officer

Simon has over 19 years of experience in Radiology and is currently doing clinical work in London as a Consultant Thoracic Radiologist. He also holds a PhD in Biomedical Imaging, specialising in fibrotic lung diseases following his Fellowship at Royal Brompton and Harefield Hospital Foundation Trust. He was previously a Consultant Thoracic Radiologist at King’s Hospital Foundation Trust. He also has a background in computer science, specialising in machine learning and computer vision. His research focuses on advanced computational imaging analysis and digital biomarker discovery in diffuse lung diseases. He is the past Imaging Chair for the European Respiratory and in 2022 was elected to the Fleischner Society, a prestigious global group of leading Respiratory Scientists, Pulmonologists and Radiologists.

Darren Gallagher

Chief Technical Officer

Darren has a wealth of experience in the software industry with a background in big data and distributed systems. His previous roles have included Head of Engineering at Autonomy and Director of Engineering, Big Data at Hewlett Packard Enterprise. He has developed software and managed teams from large multinationals to start ups. He is experienced in growing technology infrastructure and teams from pre-seed stage through to product launch and beyond.

Dr. Steven Bishop

Chief Data Officer

Steven has over 20 years of experience in healthcare and data science. As an undergraduate he studied Computer Science followed by medicine at the University of Cambridge. He later went on to undertake academic and specialist training in Anaesthesia and Intensive Care Medicine, and is a Fellow of the Royal College of Anaesthetists. Steven has a longstanding passion for computational research in healthcare, with publications in the domain of critical care pathophysiology and surgical data science. Previous to Qureight, Steven was Head of Research and Strategy at CMR Surgical and Director of Clinical, Regulatory and AI at Flok Health, and brings with him a wealth of experience in building AI solutions in MedTech and HealthTech.

Scientific Advisory Board

Principal - Open Innovation Solutions for Precision Medicine
Iqvia
Keck School of Medicine of the University of Southern California
Imperial College London
British Lung Foundation Professor
Imperial College London
Industry Expert
Industry Expert
Wythenshawe Hospital
Microsoft Health Futures

Board of Directors

Chief Executive Officer
Chair of the Board
Non Executive Director
Non Executive Director
Non Executive Director

Investors